누비서팁(Nuvisertib) 판매 예측 및 시장 규모 분석(2034년)

Key Factors Driving Nuvisertib Growth

1. First-in-class PIM1 kinase inhibitor with a differentiated mechanism of action

Nuvisertib (TP-3654) is an investigational, orally administered, highly selective PIM1 kinase inhibitor being developed by Sumitomo Pharma America for relapsed/refractory myelofibrosis (MF). PIM1 kinase plays a central role in inflammatory signaling, malignant cell survival, and bone marrow fibrosis. Unlike currently approved JAK inhibitors that primarily control symptoms, nuvisertib has demonstrated effects on inflammatory cytokines, bone marrow fibrosis, hemoglobin, and platelet counts, suggesting potential disease-modifying activity. Recent translational research also indicates that nuvisertib inhibits ACVR1, providing a mechanistic explanation for improvements in anemia through hepcidin modulation.

2. Encouraging Phase I/II efficacy supports continued clinical development

Updated data from the ongoing Phase I/II trial (NCT04176198) presented at EHA 2025 demonstrated encouraging clinical activity in heavily pretreated patients with relapsed/refractory MF. Among evaluable patients receiving nuvisertib monotherapy, 22.2% achieved >=25% spleen volume reduction (SVR25), 44.4% achieved >=50% reduction in total symptom score (TSS50), 42.9% experienced improvement in bone marrow fibrosis, while 24% showed hemoglobin improvement and 26.7% demonstrated platelet count improvement. Importantly, no dose-limiting toxicities were observed, supporting further dose optimization and clinical expansion.

3. Combination therapy with momelotinib expands the commercial opportunity

Nuvisertib is now being evaluated in combination with momelotinib, a JAK inhibitor approved for myelofibrosis with anemia. Preliminary results presented at the European Hematology Association (EHA) 2026 Congress showed that the combination was generally well tolerated in a difficult-to-treat population in which all patients had received prior JAK inhibitor therapy and 41% carried high molecular-risk mutations. Among evaluable patients treated for 24 weeks, 60% achieved responses across spleen size, symptom burden, and anemia, suggesting that dual inhibition of PIM1 and ACVR1 may provide broader clinical benefit than JAK inhibition alone. If confirmed in later-stage studies, this combination strategy could substantially expand nuvisertib's addressable patient population.

4. Regulatory designations de-risk development and accelerate the approval pathway

Nuvisertib has received both US FDA Fast Track Designation (June 2025) and European Medicines Agency (EMA) Orphan Drug Designation (July 2025) for the treatment of myelofibrosis. Fast Track designation facilitates more frequent interactions with the FDA and may enable rolling review and Priority Review, while Orphan Drug Designation provides regulatory incentives, including market exclusivity upon approval. These designations validate the significant unmet need in relapsed/refractory MF and improve the likelihood of efficient clinical and regulatory development.

Nuvisertib Recent Developments

In June 2026, Sumitomo Pharma America, Inc. (SMPA) announced the presentation of new clinical and translational research at the European Hematology Association (EHA) 2026 Congress, held from June 11-14, 2026, in Stockholm, Sweden.

Among the data is the first-ever disclosure of preliminary clinical data for the investigational PIM1 inhibitor Nuvisertib in combination with momelotinib (MMB) for patients with myelofibrosis (MF), and new translational research into the mechanistic basis for hemoglobin improvement observed in patients with MF in an ongoing Phase I/II study with nuvisertib. Alongside these findings, SMPA is also sharing new data gathered around acquired resistance patterns observed with enzomenib in acute leukemia.

"Nuvisertib Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Nuvisertib for potential indication like Myelofibrosis, Multiple myeloma, and Triple negative breast cancer in the 7MM. A detailed picture of Nuvisertib's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Nuvisertib for potential indications. The Nuvisertib market report provides insights about Nuvisertib's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Nuvisertib performance, future market assessments inclusive of the Nuvisertib market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Nuvisertib sales forecasts, along with factors driving its market.

Nuvisertib Drug Summary

Nuvisertib (TP-3654) is an investigational, orally administered PIM1 kinase inhibitor being developed for the treatment of myelofibrosis and other hematologic malignancies. Nuvisertib selectively inhibits PIM1, a serine/threonine kinase involved in cell survival, proliferation, cytokine signaling, and fibrosis, with the goal of reducing inflammatory cytokine production, improving bone marrow function, and slowing disease progression independently of the JAK-STAT pathway. In early-phase clinical studies involving patients with relapsed, refractory, or JAK inhibitor-ineligible myelofibrosis, nuvisertib demonstrated encouraging improvements in constitutional symptoms, anemia, spleen volume, and biomarkers of fibrosis, while also showing potential disease-modifying activity. The most commonly reported adverse events include nausea, diarrhea, vomiting, fatigue, and reversible elevations in liver enzymes, with an overall manageable safety profile. Although nuvisertib has not yet received regulatory approval, it continues to advance through clinical development as a promising non-JAK targeted therapy that could address unmet needs in patients with myelofibrosis, particularly those with inadequate responses or intolerance to existing JAK inhibitor treatments. The report provides Nuvisertib's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Nuvisertib Market Report

The report provides insights into:

• A comprehensive product overview including the Nuvisertib MoA, description, dosage and administration, research and development activities in potential indication like Myelofibrosis, Multiple myeloma, and Triple negative breast cancer.
• Elaborated details on Nuvisertib regulatory milestones and other development activities have been provided in Nuvisertib market report.
• The report also highlights Nuvisertib's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Nuvisertib market report also covers the patents information, generic entry and impact on cost cut.
• The Nuvisertib market report contains current and forecasted Nuvisertib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Nuvisertib market report also features the SWOT analysis with analyst views for Nuvisertib in potential indications.

Methodology:

The Nuvisertib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Nuvisertib Analytical Perspective by DelveInsight

• In-depth Nuvisertib Market Assessment

This Nuvisertib sales market forecast report provides a detailed market assessment of Nuvisertib for potential indication like Myelofibrosis, Multiple myeloma, and Triple negative breast cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Nuvisertib sales data uptil 2034.

• Nuvisertib Clinical Assessment

The Nuvisertib market report provides the clinical trials information of Nuvisertib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Nuvisertib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Nuvisertib Market Potential & Revenue Forecast

• Projected market size for the Nuvisertib and its key indications
• Estimated Nuvisertib sales potential (Nuvisertib peak sales forecasts)
• Nuvisertib Pricing strategies and reimbursement landscape

Nuvisertib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Nuvisertib Market positioning compared to existing treatments
• Nuvisertib Strengths & weaknesses relative to competitors

Nuvisertib Regulatory & Commercial Milestones

• Nuvisertib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Nuvisertib Clinical Differentiation

• Nuvisertib Efficacy & safety advantages over existing drugs
• Nuvisertib Unique selling points

Nuvisertib Market Report Highlights

• In the coming years, the Nuvisertib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Nuvisertib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Nuvisertib's dominance.
• Other emerging products for Myelofibrosis, Multiple myeloma, and Triple negative breast cancer are expected to give tough market competition to Nuvisertib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Nuvisertib in potential indications.
• Analyse Nuvisertib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Nuvisertib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Nuvisertib in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Nuvisertib? How strong is Nuvisertib's clinical and commercial performance?
• What is Nuvisertib's clinical trial status in each individual indications such as Myelofibrosis, Multiple myeloma, and Triple negative breast cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Nuvisertib Manufacturers?
• What are the key designations that have been granted to Nuvisertib for potential indications? How are they going to impact Nuvisertib's penetration in various geographies?
• What is the current and forecasted Nuvisertib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Nuvisertib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Nuvisertib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Nuvisertib? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Nuvisertib Overview in potential indication like Myelofibrosis, Multiple myeloma, and Triple negative breast cancer

• 2.1. Product Detail
• 2.2. Nuvisertib Clinical Development
  • 2.2.1. Nuvisertib Clinical studies
  • 2.2.2. Nuvisertib Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Nuvisertib Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Nuvisertib Therapies)

5. Nuvisertib Market Assessment

• 5.1. Nuvisertib Market Outlook in potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Nuvisertib Market Size in the 7MM for potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Nuvisertib Market Size in the United States for potential indications
  • 5.3.2. Nuvisertib Market Size in Germany for potential indications
  • 5.3.3. Nuvisertib Market Size in France for potential indications
  • 5.3.4. Nuvisertib Market Size in Italy for potential indications
  • 5.3.5. Nuvisertib Market Size in Spain for potential indications
  • 5.3.6. Nuvisertib Market Size in the United Kingdom for potential indications
  • 5.3.7. Nuvisertib Market Size in Japan for potential indications

6. Nuvisertib SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options